Andrew M Scott Selected Research

epidermal growth factor receptor VIII

3/2021	EGFRvIII Promotes Cell Survival during Endoplasmic Reticulum Stress through a Reticulocalbin 1-Dependent Mechanism.
1/2021	A Phase 1 and Biodistribution Study of ABT-806i, an 111In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.
1/2019	Oncogenic mutations at the EGFR ectodomain structurally converge to remove a steric hindrance on a kinase-coupled cryptic epitope.
7/2017	Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.
1/2016	Control of glioblastoma tumorigenesis by feed-forward cytokine signaling.
5/2015	Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.
6/2012	Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy.
9/2011	Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism.
4/2011	Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation.
10/2010	MAb 806 enhances the efficacy of ionizing radiation in glioma xenografts expressing the de2-7 epidermal growth factor receptor.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrew M Scott Research Topics

Disease

151	Neoplasms (Cancer) 04/2024 - 02/2002
25	Glioblastoma (Glioblastoma Multiforme) 04/2024 - 05/2009
21	Prostatic Neoplasms (Prostate Cancer) 11/2023 - 07/2005
18	Hypoxia (Hypoxemia) 01/2020 - 02/2002
17	Neoplasm Metastasis (Metastasis) 01/2022 - 06/2004
15	Glioma (Gliomas) 01/2024 - 02/2002
14	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 07/2005
11	Renal Cell Carcinoma (Grawitz Tumor) 02/2024 - 05/2002
10	Carcinoma (Carcinomatosis) 01/2018 - 08/2003
9	Melanoma (Melanoma, Malignant) 01/2024 - 10/2002
7	Breast Neoplasms (Breast Cancer) 09/2023 - 08/2003
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 06/2004
4	Lymphoma (Lymphomas) 01/2023 - 03/2012
4	Disease Progression 01/2021 - 06/2010
4	Brain Neoplasms (Brain Tumor) 01/2021 - 02/2002
4	Malignant Mesothelioma 12/2020 - 06/2011
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 05/2015 - 02/2007
4	Lung Neoplasms (Lung Cancer) 06/2009 - 06/2004
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 11/2022 - 03/2009
3	Mesothelioma 10/2020 - 06/2011
3	Ischemic Stroke 01/2018 - 08/2012
2	Cachexia 11/2022 - 09/2015
2	Hodgkin Disease (Hodgkin's Disease) 11/2022 - 02/2022
2	Hematologic Neoplasms (Hematological Malignancy) 03/2022 - 10/2017
2	Hypertension (High Blood Pressure) 01/2022 - 02/2009

Drug/Important Bio-Agent (IBA)

39	Monoclonal AntibodiesIBA 02/2024 - 03/2002
32	AntibodiesIBA 11/2022 - 03/2002
32	ErbB Receptors (EGF Receptor)IBA 01/2021 - 01/2003
31	AntigensIBA 11/2023 - 05/2002
23	Proteins (Proteins, Gene)FDA Link 03/2023 - 05/2002
18	epidermal growth factor receptor VIIIIBA 03/2021 - 03/2002
17	Immunoconjugates (Immunoconjugate)IBA 07/2023 - 11/2009
13	LigandsIBA 01/2023 - 08/2004
13	monoclonal antibody 806IBA 05/2015 - 03/2002
12	fluoromisonidazoleIBA 01/2020 - 02/2002
10	EpitopesIBA 10/2020 - 07/2004
9	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2024 - 03/2006
8	Tyrosine (L-Tyrosine)FDA Link 04/2024 - 06/2009
8	Radioisotopes (Radionuclides)IBA 08/2023 - 02/2007
7	Phosphotransferases (Kinase)IBA 09/2023 - 02/2007
7	Eph Family Receptors (Eph Receptors)IBA 01/2023 - 02/2012
7	Biomarkers (Surrogate Marker)IBA 01/2023 - 10/2018
7	depatuxizumab mafodotinIBA 01/2021 - 12/2017
7	Tyrosine Kinase InhibitorsIBA 01/2018 - 10/2005
7	Glucose (Dextrose)FDA LinkGeneric 07/2012 - 06/2004
6	EnzymesIBA 02/2024 - 12/2006
6	EphrinsIBA 01/2023 - 08/2005
6	CarbohydratesIBA 10/2015 - 07/2004
6	Hu3S193 monoclonal antibodyIBA 08/2015 - 08/2003
5	Temozolomide (Temodar)FDA LinkGeneric 01/2021 - 12/2003
5	CytokinesIBA 09/2019 - 05/2002
5	VaccinesIBA 01/2017 - 07/2004
4	Carbonic Anhydrase IXIBA 02/2024 - 07/2009
4	Lutetium-177IBA 11/2023 - 01/2009
4	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2022 - 12/2003
4	Androgen Receptors (Androgen Receptor)IBA 01/2021 - 01/2016
4	depatuxizumabIBA 01/2021 - 05/2015
4	Cetuximab (Erbitux)FDA Link 11/2015 - 02/2007
4	Therapeutic UsesIBA 11/2015 - 02/2007
4	Blood Group Antigens (Blood Groups)IBA 10/2015 - 07/2004
4	Lewis Y antigenIBA 08/2015 - 06/2007
4	PolymersIBA 08/2012 - 09/2007
3	cabazitaxel FDA Link 11/2023 - 01/2021
3	Docetaxel (Taxotere)FDA Link 11/2023 - 01/2009
3	EphA1 Receptor (Eph Receptor)IBA 09/2023 - 08/2014
3	Fluorine-18IBA 03/2023 - 06/2004
3	Immune Checkpoint InhibitorsIBA 01/2023 - 01/2022
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 11/2015
3	Indicators and Reagents (Reagents)IBA 12/2021 - 08/2005
3	LipidsIBA 01/2021 - 11/2019
3	AndrogensIBA 01/2021 - 06/2009
3	ABT-414IBA 10/2020 - 07/2017
3	Cytotoxins (Cytolysins)IBA 01/2019 - 12/2005
3	Platelet-Derived Growth FactorIBA 01/2018 - 01/2018
3	platelet-derived growth factor C (PDGF-C)IBA 01/2018 - 01/2018
3	Epidermal Growth Factor (EGF)IBA 01/2016 - 06/2009
3	DisulfidesIBA 01/2016 - 09/2011
3	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 01/2016 - 11/2013
3	SulfoxidesIBA 01/2016 - 08/2012
3	Serine Proteases (Serine Protease)IBA 11/2015 - 11/2012
3	Immunoglobulin G (IgG)IBA 08/2015 - 08/2008
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2015 - 04/2006
3	Interleukin-2 (IL2)IBA 08/2007 - 05/2002
2	Chimeric Antigen ReceptorsIBA 04/2024 - 11/2013
2	Prostate-Specific Antigen (Semenogelase)IBA 11/2023 - 11/2022
2	RNA (Ribonucleic Acid)IBA 09/2023 - 11/2022
2	InterferonsIBA 01/2023 - 10/2013
2	Peptides (Polypeptides)IBA 01/2023 - 01/2016
2	Capecitabine (Xeloda)FDA Link 01/2022 - 04/2014
2	Bevacizumab (Avastin)FDA Link 01/2022 - 11/2015
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 03/2021 - 12/2020
2	Phospholipids (Phosphatides)FDA LinkGeneric 01/2021 - 01/2021

Therapy/Procedure

79	Therapeutics 02/2024 - 03/2002
21	Drug Therapy (Chemotherapy) 01/2023 - 09/2005
16	Radiotherapy 06/2023 - 09/2005
12	Immunotherapy 11/2022 - 05/2002
10	Radioimmunotherapy 12/2016 - 07/2005
6	Castration 11/2023 - 10/2018
5	Precision Medicine 08/2023 - 01/2019
3	Prostatectomy (Retropubic Prostatectomy) 01/2019 - 05/2011